# Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

> **NCT02400242** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 85 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ACY-241
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02400242
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-07
- **Primary completion:** 2024-06-03
- **Final completion:** 2024-06-03
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02400242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02400242, "Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02400242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*